Why ResMed Investors Can Sleep Well at Night
In his 2018 book Factfulness, Hans Rosling points out what he calls humans' "gap instinct" -- "that irresistible temptation we have to divide all kinds of things into two distinct and often conflicting groups." This oversimplification also applies to investors. Consuming financial media may convince you that you have to choose between fast-growing, cash-burning technology companies or 100-year-old businesses that are no longer growing but appear to be safer and cheaper choices.
ResMed (NYSE: RMD), a maker of devices and masks for sleep disorders and respiratory diseases, is just the kind of middle-ground investment that could reward both types of investors. The company focuses primarily on treatments for sleep apnea (an interruption to breathing due to airway obstruction), chronic pulmonary obstructive disorder (COPD, the obstruction of airflow to the lungs due to inflammation), and asthma (a condition in which the airways swell and produce extra mucus that interferes with normal breathing).
Image source: Getty Images.
Source Fool.com
